Abbvie Inc
NYSE: ABBV
$177.14
+$0.19 (+0.1%)
Real Time Data Delayed 15 Min.
ABBV Articles
Thursday's top analyst upgrades and downgrades from 24/7 Wall St. include ARIAD Pharmaceuticals, FedEx, Genpact, Suncor Energy, Travelers and UPS.
Published:
Friday's top analyst upgrades, downgrades and initiations include Harley-Davidson, Lululemon, Nike, SunPower and Walmart.
Published:
A new research report from the analysts at UBS focuses on four companies that stand to benefit from rising demand for the drugs they produce that treat hepatitis C.
Published:
Only one of the seven stocks traded on the New York Stock Exchange with the largest number of shares held short as of October 15 experienced a decline in short interest.
Published:
Last Updated:
UBS polled all of its analysts, who came up with 26 stocks by now. Here are the ones that offer large cap growth with the best upside.
Published:
The most shorted stocks on the New York Stock Exchange at the September 30 settlement dates saw rising short interest during the two-week period.
Published:
Short sellers shied away from Bank of American enough that it slipped out of the top five most shorted stocks on the New York Stock Exchange.
Published:
The U.S. Treasury has finally made its proposed effort to deal with the waves of corporate tax inversions that have created such a stir of late.
Published:
A new research report from UBS focuses on four top companies that are making great strides in treatments for patients -- and generating gigantic revenues.
Published:
Surges in short interest between the August 15 and August 29 settlement dates pushed Sprint into the top five most shorted stocks on the New York Stock Exchange.
Published:
Infinity Pharmaceuticals will partner with Abbvie to further develop and commercialize IPI-145, also known as Duvelisib.
Published:
A new report from the pharmaceutical team at Credit Suisse highlights four top stocks to buy for the remainder of 2014
Published:
AbbVie reported better-than-expected second-quarter 2014 results before markets opened Friday morning, due in part to strong sales of its Humira anti-inflammatory drug.
Published:
Last Updated:
These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Tuesday, July 2, 2014. They include Alcatel-Lucent, Apple, FireEye, JDSU Uniphase and solar stocks.
Published:
ThinkstockAs the summer starts, a large agenda is out there for investors when it comes to top biotech and specialty pharmaceutical companies making announcements and presenting clinical data. The...
Published: